STOCK TITAN

Reshape Lifesciences Stock Price, News & Analysis

RSLS NASDAQ

Company Description

Overview

Reshape Lifesciences Inc. (RSLS) is a development-stage medical device company dedicated to advancing treatment approaches for obesity and metabolic diseases. Specializing in non-surgical weight loss solutions and innovative health technologies, the company seeks to bridge the gap between conventional pharmacological interventions and invasive surgical procedures. Its solutions are crafted to support patients who are seeking effective, less intrusive alternatives in managing weight and associated metabolic conditions.

Core Technologies and Product Portfolio

The company has developed a diversified portfolio of medical solutions designed to enhance patient outcomes and improve the treatment experience. Among its offerings are:

  • Adjustable Gastric Banding System: An approach aimed at providing a customizable and reversible option for weight management, addressing the needs of patients cautious of surgical interventions.
  • Swallowable Balloon System: A novel, gas-filled device that offers a non-surgical option for temporary weight reduction, appealing to individuals seeking minimally invasive methods.
  • ReShapeCare Virtual Health Coaching: An integrated digital platform that combines personalized guidance with technological support to help patients adhere to weight management programs.
  • Metabolic Health Solutions: Innovations such as the Diabetes Bloc-Stim Neuromodulation, designed to provide a new therapeutic approach in the treatment of type 2 diabetes mellitus.

Market Position and Industry Context

Operating in a rapidly evolving field of medical devices and digital health, Reshape Lifesciences occupies a significant niche in the obesity and metabolic disease treatment markets. This industry is characterized by a continuous search for safer, less invasive alternatives for weight loss and chronic disease management. The company differentiates itself by offering a range of complementary solutions that address both the physiological and behavioral aspects of weight management. Its products are designed to be integrated into a broader treatment ecosystem, appealing to healthcare providers who prioritize patient safety and recovery.

Competitive Landscape and Differentiators

Within the competitive environment of medical device innovation, Reshape Lifesciences faces challenges that include regulatory compliance, technological validation, and market adoption. However, its comprehensive portfolio, combining established device designs with emerging digital health strategies, sets it apart from companies solely focused on surgical solutions. By emphasizing less invasive approaches, the company positions itself as an attractive option for patients wary of traditional surgeries, while also appealing to healthcare practitioners keen on combining technology with patient care. This strategic blend of device innovation and digital health integration reinforces its commitment to enhancing treatment outcomes.

Commitment to Innovation and Patient-Centric Solutions

At the core of Reshape Lifesciences' mission is a commitment to making weight loss and metabolic disease management more accessible and safer. The development of non-surgical devices not only reduces the potential risks associated with invasive surgeries but also augments traditional weight loss methods through supportive digital interventions like virtual health coaching. This patient-centric focus underscores the company’s dedication to delivering tools and therapies that are both innovative and aligned with clinical needs.

Understanding the Business Model

The company operates by leveraging research and development to drive innovation within the medical device sector. Its business model is built on creating and commercializing products that serve a critical need in the field of weight and metabolic health management. Revenue generation is linked to a combination of device sales, digital platform subscriptions, and potential licensing opportunities. This multifaceted approach allows the company to address varied patient and provider needs while sustaining ongoing advancements through continuous product refinements.

Summary

Reshape Lifesciences Inc. represents a forward-thinking approach in the realm of medical devices focusing on non-surgical weight loss and metabolic health. Its combination of established and emerging technologies provides a robust framework for addressing the challenges associated with obesity and type 2 diabetes treatment. With an emphasis on patient safety, technological integration, and comprehensive treatment solutions, the company is positioned as a key player in a niche that values innovation, efficacy, and a balanced approach to healthcare solutions.

Stock Performance

$0.3663
+0.36%
+0.00
Last updated: April 26, 2025 at 19:50
-71.18 %
Performance 1 year
$3.5M
Market Cap
11.3M
Shares outstanding

SEC Filings

No SEC filings available for Reshape Lifesciences.

Financial Highlights

$2,292,000
Revenue (TTM)
-$1,581,000
Net Income (TTM)
-$3.11
Diluted EPS (TTM)
-$311,000
Operating Cash Flow
-68.98%
Net Profit Margin
-76.83%
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Reshape Lifesciences (RSLS)?

The current stock price of Reshape Lifesciences (RSLS) is $0.365 as of April 25, 2025.

What is the market cap of Reshape Lifesciences (RSLS)?

The market cap of Reshape Lifesciences (RSLS) is approximately 3.5M.

What is the revenue (TTM) of Reshape Lifesciences (RSLS) stock?

The trailing twelve months (TTM) revenue of Reshape Lifesciences (RSLS) is $2,292,000.

What is the net income of Reshape Lifesciences (RSLS)?

The trailing twelve months (TTM) net income of Reshape Lifesciences (RSLS) is -$1,581,000.

What is the earnings per share (EPS) of Reshape Lifesciences (RSLS)?

The diluted earnings per share (EPS) of Reshape Lifesciences (RSLS) is -$3.11 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Reshape Lifesciences (RSLS)?

The operating cash flow of Reshape Lifesciences (RSLS) is -$311,000.

What is the profit margin of Reshape Lifesciences (RSLS)?

The net profit margin of Reshape Lifesciences (RSLS) is -68.98%.

What is the operating margin of Reshape Lifesciences (RSLS)?

The operating profit margin of Reshape Lifesciences (RSLS) is -76.83%.

What is the gross margin of Reshape Lifesciences (RSLS)?

The gross profit margin of Reshape Lifesciences (RSLS) is 62.78%.

What is the current ratio of Reshape Lifesciences (RSLS)?

The current ratio of Reshape Lifesciences (RSLS) is 1.33, indicating the company's ability to pay short-term obligations.

What is the gross profit of Reshape Lifesciences (RSLS)?

The gross profit of Reshape Lifesciences (RSLS) is $1,439,000 on a trailing twelve months (TTM) basis.

What is the operating income of Reshape Lifesciences (RSLS)?

The operating income of Reshape Lifesciences (RSLS) is -$1,761,000.

What is the primary focus of Reshape Lifesciences Inc.?

Reshape Lifesciences Inc. focuses on developing non-surgical medical devices and digital health solutions for weight loss and metabolic diseases.

How does the company address obesity treatment?

The company offers innovative devices such as adjustable gastric banding systems and swallowable balloon systems that provide less invasive alternatives to traditional surgery.

What types of products does Reshape Lifesciences include in its portfolio?

Their portfolio includes devices for weight management and emerging solutions for metabolic health, along with digital health initiatives like virtual coaching platforms.

How does the company integrate digital health into its product offerings?

Reshape Lifesciences integrates digital health through programs like ReShapeCare, a virtual health coaching service designed to enhance patient adherence and support overall well-being.

What sets Reshape Lifesciences apart from traditional surgical solutions?

Their focus on less invasive, patient-centric alternatives provides options for those who prefer non-surgical therapeutic interventions over conventional invasive procedures.

In which market segments does Reshape Lifesciences operate?

The company operates in the medical device sector with a focus on weight management, obesity treatment, and metabolic health solutions, targeting both patients and healthcare providers.

What are the key benefits of the company’s product approaches?

Their approaches provide safer and potentially more comfortable treatment options that reduce the risks associated with invasive surgeries, combining device innovation with digital support.

How is Reshape Lifesciences positioned within the competitive landscape?

The company differentiates itself through its diverse product portfolio and commitment to innovation in non-surgical weight loss and metabolic therapies, aiming to address a significant unmet need in patient care.